Interleukin 10 (IL-10) is secreted by several hemopoietic cells and suppresses the Th1 mediated immune response, while stimulating B cell differentiation and the humoral immune response. IL-10 expression in Con A-stimulated peripheral blood mononuclear cells is related to three polymorphisms in the promoter region of the IL-10 gene; G/A at position − 1082, T/C at position − 819 and A/C at position − 592. We analyzed the distribution of these IL-10 polymorphisms in 64 MG patients and 87 healthy blood donors to determine any influence on MG susceptibility. MG patients had a significantly higher frequency of the ACC/ACC haplotype (12.5% vs 3.4% in controls), as had the subgroups with late onset MG and thymomatous MG (20.0% and 21.4%, respectively). Early onset MG patients had a high frequency of the ATA/ATA haplotype (19.2% vs 3.4% in controls). Titin Ab-positive MG patients had high ACC/ACC (20.0%). This study indicates a direct link between IL-10 and MG pathogenesis, although the complex role of this multi-faceted cytokine in vivo is as yet not fully elucidated.
Introduction
Myasthenia gravis (MG) is an autoimmune disease characterized by fluctuating pathological weakness involving skeletal muscle. It is primarily caused by antibodies (Abs) to the nicotinic acetylcholine receptor (AChR) at the postsynaptic site of the neuromuscular junction (Vincent and Drachman, 2002; Hughes et al., 2004 ). The disease is heterogeneous and is classified by age at onset and thymus pathology. In 30% of MG patients, onset is early (EO-MG; onset before age 50 years), and in 60% onset is late (LO-MG; onset at age 50 years or older). The remaining 10% of patients have a thymoma (Somnier, 1996) 
